Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022327 · ClinicalTrials.gov registry record
Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.
A clinical trial of Chronic Pancreatitis, sponsored by Mission: Cure.
- Active
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT07022327: Active study of Chronic Pancreatitis, sponsored by Mission: Cure.
NCT07022327 is a study of Chronic Pancreatitis that is active but no longer recruiting, run by Mission: Cure. The registered enrollment target is 1 participants, below the 689-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07022327, a study of Chronic Pancreatitis, is active but no longer recruiting, sponsored by Mission: Cure.
- ACTIVE NOT RECRUITING
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about the long-term effects of Ivacaftor in an adolescent without a cystic fibrosis-associated CFTR mutation who is taking Ivacaftor to treat chronic pancreatitis. The main question it aims to answer is: Does Ivacaftor reduce the frequency or severity of acute pancreatitis episodes in this adolescent compared to their historical medical data? The participant, who is already taking Ivacaftor as part of their medical care, will be monitored over the course of 12 months. Flare frequency, hospitalizations, and wellness data will be tracked through caregiver reports, lab data, and physiological data collected from a wearable health monitoring device (Apple Watch).
Primary Outcome
The number of days between clinically confirmed acute pancreatitis attacks during the 12-month Ivacaftor treatment period, compared to historical pre-treatment intervals.
Conditions Studied
Interventions
- DRUG Ivacaftor 150 MG (milligrams)
Study Locations (1)
Washington
- Mission: Cure - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2026-08 |
What the registry record for NCT07022327 still lists
NCT07022327 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 689-participant average among 42 other Chronic Pancreatitis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Chronic Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which Ivacaftor 150 MG (milligrams) is the first listed.
NCT07022327 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT07022327 about?
NCT07022327 is a clinical study titled "Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.". The goal of this observational study is to learn about the long-term effects of Ivacaftor in an adolescent without a cystic fibrosis-associated CFTR mutation who is taking Ivacaftor to treat chronic pancreatitis. The main question it aims to answer is: Does Ivacaftor reduce the frequency or severit...
What is the current status of trial NCT07022327?
This trial is currently active not recruiting. The enrollment target is 1 participants. The study started on 2025-05-06. Estimated completion is 2026-08.
What conditions does trial NCT07022327 study?
This clinical trial studies the following conditions: Chronic Pancreatitis.
What interventions are being tested in trial NCT07022327?
The interventions under investigation include: Ivacaftor 150 MG (milligrams) (DRUG).
Who is sponsoring clinical trial NCT07022327?
This trial is sponsored by Mission: Cure, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022327 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07022327's enrollment target sits among peer trials
1 43rd of 42 the lowest of 42 other Chronic Pancreatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
-
Analysis of Graft Function Following Autologous Islet Transplantation
RECRUITING
-
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
RECRUITING · Early Phase 1
-
Scrambler Therapy in Chronic Pancreatitis
RECRUITING · NA
-
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
RECRUITING
-
Pancreas Registry and High Risk Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI